1
|
Wu X, Ma Y, Wang L, Qin X. A Route for Investigating Psoriasis: From the Perspective of the Pathological Mechanisms and Therapeutic Strategies of Cancer. Int J Mol Sci 2023; 24:14390. [PMID: 37762693 PMCID: PMC10532365 DOI: 10.3390/ijms241814390] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/14/2023] [Revised: 09/20/2023] [Accepted: 09/20/2023] [Indexed: 09/29/2023] Open
Abstract
Psoriasis is an incurable skin disease that develops in about two-thirds of patients before the age of 40 and requires lifelong treatment; its pathological mechanisms have not been fully elucidated. The core pathological process of psoriasis is epidermal thickening caused by the excessive proliferation of epidermal keratinocytes, which is similar to the key feature of cancer; the malignant proliferation of cancer cells causes tumor enlargement, suggesting that there is a certain degree of commonality between psoriasis and cancer. This article reviews the pathological mechanisms that are common to psoriasis and cancer, including the interaction between cell proliferation and an abnormal immune microenvironment, metabolic reprogramming, and epigenetic reprogramming. In addition, there are common therapeutic agents and drug targets between psoriasis and cancer. Thus, psoriasis and cancer share a common pathological mechanisms-drug targets-therapeutic agents framework. On this basis, it is proposed that investigating psoriasis from a cancer perspective is beneficial to enriching the research strategies related to psoriasis.
Collapse
Affiliation(s)
- Xingkang Wu
- Modern Research Center for Traditional Chinese Medicine, The Key Laboratory of Chemical Biology and Molecular Engineering of Ministry of Education, Shanxi University, No. 92, Wucheng Road, Taiyuan 030006, China; (Y.M.); (L.W.)
| | | | | | - Xuemei Qin
- Modern Research Center for Traditional Chinese Medicine, The Key Laboratory of Chemical Biology and Molecular Engineering of Ministry of Education, Shanxi University, No. 92, Wucheng Road, Taiyuan 030006, China; (Y.M.); (L.W.)
| |
Collapse
|
2
|
Gu Y, Li K, Zhou Y, Zhang J. Chronic myeloid leukaemia in a patient with psoriasis following bimolane treatment. J Eur Acad Dermatol Venereol 2020; 34:e66-e67. [PMID: 31465597 DOI: 10.1111/jdv.15915] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Affiliation(s)
- Y Gu
- Department of Dermatology, Peking University People's Hospital, Beijing, China
| | - K Li
- Department of Dermatology, Peking University People's Hospital, Beijing, China
| | - Y Zhou
- Department of Hematology, Peking University People's Hospital, Beijing, China
| | - J Zhang
- Department of Dermatology, Peking University People's Hospital, Beijing, China
| |
Collapse
|
3
|
Ge F, Zhang Y, Cao F, Li J, Hou J, Wang P, Li H, Xu M, Liu S, Li L, Li X, Wang S, Lv C, Su Y, Zhou J. Arsenic trioxide-based therapy is suitable for patients with psoriasis-associated acute promyelocytic leukemia - A retrospective clinical study. ACTA ACUST UNITED AC 2016; 21:287-94. [PMID: 26871996 DOI: 10.1080/10245332.2015.1115586] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
Abstract
OBJECTIVE Many patients with psoriasis have developed acute promyelocytic leukemia (APL) whereas few reports on psoriasis-associated APL were found in the published literature. This study was aimed to study the etiology, clinical characteristics, and prognosis of psoriasis-associated APL and to map a suitable treatment regime for this condition. METHODS This study retrospectively analyzed the clinical data of 17 patients with psoriasis-associated APL diagnosed and treated in our hospital in the past decade. RESULTS The 17 patients accounted for 8.3% of the total patients diagnosed with de novo APL during the same period in our hospital. Their clinical characteristics of APL were similar to those of general APL. Four patients had a definite history of taking bimolane. All patients received arsenic trioxide (ATO)-based remission induction and postremission treatment. After induction, 15 patients (88%) achieved hematologic complete remission. With a median follow-up of 27 months, the 3-year estimates of overall survival were 77.2% ± 12.4% and the 3-year estimates of event-free survival were 70.6% ± 13.5%. In addition, the ATO-based remission induction and postremission treatment significantly improved psoriasis symptoms in 83 and 85.7% of patients, respectively. Through the final follow-up, no chronic arsenicosis or secondary malignancy was observed. CONCLUSIONS Psoriasis patients are at high risk for APL. The increased risk is most likely associated with the genetic background and bimolane treatment. The ATO-based therapy is especially suitable for patients with psoriasis-associated APL. Our study also brings a new treatment option for psoriasis.
Collapse
Affiliation(s)
- Fei Ge
- a Department of Hematology , The First Affiliated Hospital, Harbin Medical University , China
| | - Yingmei Zhang
- b Central Laboratory , The First Affiliated Hospital, Harbin Medical University , China
| | - Fenglin Cao
- b Central Laboratory , The First Affiliated Hospital, Harbin Medical University , China
| | - Jinmei Li
- a Department of Hematology , The First Affiliated Hospital, Harbin Medical University , China
| | - Jinxiao Hou
- a Department of Hematology , The First Affiliated Hospital, Harbin Medical University , China
| | - Ping Wang
- a Department of Hematology , The First Affiliated Hospital, Harbin Medical University , China.,c Department of Neonatology , The First Affiliated Hospital, Harbin Medical University , China
| | - Haitao Li
- a Department of Hematology , The First Affiliated Hospital, Harbin Medical University , China
| | - Mengyuan Xu
- a Department of Hematology , The First Affiliated Hospital, Harbin Medical University , China
| | - Shuchuan Liu
- a Department of Hematology , The First Affiliated Hospital, Harbin Medical University , China
| | - Limin Li
- a Department of Hematology , The First Affiliated Hospital, Harbin Medical University , China
| | - Xiaoxia Li
- a Department of Hematology , The First Affiliated Hospital, Harbin Medical University , China
| | - Shuye Wang
- a Department of Hematology , The First Affiliated Hospital, Harbin Medical University , China
| | - Chengfang Lv
- a Department of Hematology , The First Affiliated Hospital, Harbin Medical University , China
| | - Yanhua Su
- a Department of Hematology , The First Affiliated Hospital, Harbin Medical University , China
| | - Jin Zhou
- a Department of Hematology , The First Affiliated Hospital, Harbin Medical University , China.,b Central Laboratory , The First Affiliated Hospital, Harbin Medical University , China
| |
Collapse
|
4
|
Vuong MC, Hasegawa LS, Eastmond DA. A comparative study of the cytotoxic and genotoxic effects of ICRF-154 and bimolane, two catalytic inhibitors of topoisomerase II. Mutat Res 2012; 750:63-71. [PMID: 23000430 DOI: 10.1016/j.mrgentox.2012.09.005] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/18/2012] [Revised: 09/11/2012] [Accepted: 09/13/2012] [Indexed: 11/16/2022]
Abstract
ICRF-154 and bimolane have been used for the treatment of cancer, psoriasis, and uveitis in humans. Previous reports have revealed that the two drugs are topoisomerase II catalytic inhibitors, and patients treated with these agents have developed unique types of secondary leukemia. A study published in 1984 by Camerman and colleagues proposed that the therapeutic effects of bimolane could be due to ICRF-154, an impurity present within the bimolane samples that may also be responsible for the toxic effects attributed to bimolane. To date, this hypothesis has not been evaluated. In addition, little is known about the potential cytotoxic and genotoxic effects of ICRF-154. In this study, a combination of in vitro tests in human TK6 lymphoblastoid cells has been used to characterize the cytotoxic and genotoxic effects of ICRF-154 and bimolane as well as to compare the results for the two chemicals. ICRF-154 and bimolane were both cytotoxic, exhibiting very similar effects in three measures of cytotoxicity and cell proliferation. In the cytokinesis-block micronucleus assay with CREST-antibody staining, the two agents similarly induced chromosome breakage and, to a lesser extent, chromosome loss. Intriguingly, both drugs resulted in the formation of binucleated cells, perhaps as a consequence of an interference with cytokinesis. To further investigate their aneugenic effects, flow cytometry and fluorescence in situ hybridization analyses revealed that both compounds also produced similar levels of non-disjunction and polyploidy. In each of the cellular and cytogenetic assays employed, the responses of the ICRF-154-treated cells were very similar to those observed with the bimolane, and generally occurred at equimolar test concentrations. Our results, combined with those from previous studies, strongly suggest that bimolane degrades to ICRF-154, and that ICRF-154 is most likely the chemical species responsible for the cytotoxic, genotoxic, and leukemogenic effects exerted by bimolane.
Collapse
Affiliation(s)
- Minh C Vuong
- Environmental Toxicology Graduate Program and Department of Cell Biology & Neuroscience, University of California, Riverside, CA 92521, USA
| | | | | |
Collapse
|
5
|
Roy SK, Eastmond DA. Bimolane induces multiple types of chromosomal aberrations in human lymphocytes in vitro. Mutat Res 2011; 726:181-7. [PMID: 21944901 DOI: 10.1016/j.mrgentox.2011.09.006] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2011] [Revised: 09/09/2011] [Accepted: 09/10/2011] [Indexed: 10/25/2022]
Abstract
Bimolane has been commonly used in China for the treatment of psoriasis and various types of cancer. Patients treated with bimolane have been reported to have an increased risk of developing therapy-related leukemias. Although bimolane has been identified as a human leukemia-inducing agent, little is known about its genotoxic effects, and a systematic study of the types of chromosomal alterations induced by this compound has not been performed. In this study, a combination of immunochemical, molecular and conventional cytogenetic techniques has been used to study the chromosomal alterations induced by bimolane in cultured human lymphocytes. Immunochemical staining with the CREST antibody indicated that bimolane induces micronuclei (MN) originating primarily from chromosome breakage. Interestingly fluorescence in situ hybridization (FISH) with differentially labeled chromosomes 1 and 9 centromeric probes indicated that bimolane also caused non-disjunction and polyploidy. Consistent with this, an expedited analysis of Giemsa-stained metaphase chromosomes in bimolane-treated lymphocytes revealed a high frequency of polyploidy/hyperdiploidy as well as dicentric chromosomes, and premature centromeric division (PCD). In addition, bimolane was also found to produce binucleated cells, possibly through an interference with normal functioning of intermediate filaments. As a follow-up to these studies, three different types of commercially available bimolane formulations obtained from different Chinese manufacturers were also evaluated. The effects seen with the formulated bimolane were similar to those seen with the synthesized compound. Our studies indicate that bimolane effectively induces a variety of cellular and chromosomal changes in cultured lymphocytes and that similar alterations occurring in bone marrow stem cells could contribute to the development of the secondary cancers seen in bimolane-treated patients.
Collapse
Affiliation(s)
- Shambhu K Roy
- Department of Cell Biology & Neuroscience, University of California, Riverside, CA 92521, USA
| | | |
Collapse
|
6
|
Wang Y, Mi Y, Li D, Xue Y, Bian S, Wang J. Acute leukemia association with psoriasis: a report on 100 patients from a single center in China. Am J Hematol 2010; 85:378-9. [PMID: 20425800 DOI: 10.1002/ajh.21683] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
7
|
Ramkumar B, Chadha MK, Barcos M, Sait SNJ, Heyman MR, Baer MR. Acute promyelocytic leukemia after mitoxantrone therapy for multiple sclerosis. ACTA ACUST UNITED AC 2008; 182:126-9. [PMID: 18406875 DOI: 10.1016/j.cancergencyto.2008.01.004] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/26/2007] [Accepted: 01/08/2008] [Indexed: 11/30/2022]
Abstract
Mitoxantrone is a DNA-topoisomerase 2 inhibitor used as a single agent for treatment of relapsing-remitting or progressive multiple sclerosis (MS). We present here two patients treated with mitoxantrone for MS who subsequently developed acute promyelocytic leukemia (APL). These constitute, to our knowledge, the eighth and ninth reports of APL in patients treated with mitoxantrone for MS. Topoisomerase 2 inhibitors are associated with therapy-related acute myeloid leukemia (t-AML) with 11q23 abnormalities, but therapy-related APL (t-APL) is less common, and documentation of nine cases of t-APL after mitoxantrone therapy for MS suggests a specific association.
Collapse
Affiliation(s)
- Bhuvaneswari Ramkumar
- Department of Internal Medicine, Rochester General Hospital, Rochester, NY 14621, USA
| | | | | | | | | | | |
Collapse
|
8
|
Synthesis, characterization and metal chelating properties of silica-physisorbed and chemisorbed-2,5-dioxypiperazine. Polyhedron 2007. [DOI: 10.1016/j.poly.2007.04.042] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|
9
|
Gadelle D, Graille M, Forterre P. The HSP90 and DNA topoisomerase VI inhibitor radicicol also inhibits human type II DNA topoisomerase. Biochem Pharmacol 2006; 72:1207-16. [PMID: 16959221 DOI: 10.1016/j.bcp.2006.07.040] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2006] [Revised: 07/20/2006] [Accepted: 07/24/2006] [Indexed: 12/13/2022]
Abstract
Radicicol derivatives are currently investigated as promising antitumoral drugs because they inhibit the activity of the molecular chaperone heat shock protein (HSP90), causing the destabilization and eventual degradation of HSP90 client proteins that are often associated with tumor cells. These drugs interact with the ATP-binding site of HSP90 which is characterized by a structural element known as the Bergerat fold, also present in type II DNA topoisomerases (Topo II). We have previously shown that radicicol inhibits archaeal DNA topoisomerase VI, the prototype of Topo II of the B family (present in archaea, some bacteria and all the plants sequenced so far). We show here that radicicol also inhibits the human Topo II, a member of the A family (comprising the eukaryotic Topo II, bacterial gyrase, Topo IV and viral Topo II), which is a major target for antitumoral drugs. In addition, radicicol prevents in vitro induction of DNA cleavage by human Topo II in the presence of the antitumoral drug etoposide. The finding that radicicol can inhibit at least two different antitumoral drug targets in human, and interferes with drugs currently used in cancer treatment, could have implications in cancer therapy.
Collapse
Affiliation(s)
- Danièle Gadelle
- Institut de Genetique et Microbiologie, UMR CNRS 8621, France.
| | | | | |
Collapse
|
10
|
Abstract
The potential role of genotoxicity in human leukemias associated with benzene (BZ) exposures was investigated by a systematic review of over 1400 genotoxicity test results for BZ and its metabolites. Studies of rodents exposed to radiolabeled BZ found a low level of radiolabel in isolated DNA with no preferential binding in target tissues of neoplasia. Adducts were not identified by 32P-postlabeling (equivalent to a covalent binding index <0.002) under the dosage conditions producing neoplasia in the rodent bioassays, and this method would have detected adducts at 1/10,000th the levels reported in the DNA-binding studies. Adducts were detected by 32P-postlabeling in vitro and following high acute BZ doses in vivo, but levels were about 100-fold less than those found by DNA binding. These findings suggest that DNA-adduct formation may not be a significant mechanism for BZ-induced neoplasia in rodents. The evaluation of other genotoxicity test results revealed that BZ and its metabolites did not produce reverse mutations in Salmonella typhimurium but were clastogenic and aneugenic, producing micronuclei, chromosomal aberrations, sister chromatid exchanges and DNA strand breaks. Rodent and human data were compared, and BZ genotoxicity results in both were similar for the available tests. Also, the biotransformation of BZ was qualitatively similar in rodents, humans and non-human primates, further indicating that rodent and human genotoxicity data were compatible. The genotoxicity test results for BZ and its metabolites were the most similar to those of topoisomerase II inhibitors and provided less support for proposed mechanisms involving DNA reactivity, mitotic spindle poisoning or oxidative DNA damage as genotoxic mechanisms; all of which have been demonstrated experimentally for BZ or its metabolites. Studies of the chromosomal translocations found in BZ-exposed persons and secondary human leukemias produced by topoisomerase II inhibitors provide some additional support for this mechanism being potentially operative in BZ-induced leukemia.
Collapse
Affiliation(s)
- John Whysner
- Division of Pathology and Toxicology, American Heath Foundation, 1 Dana Road, Valhalla, NY 10595, USA.
| | | | | | | | | |
Collapse
|